Neoplasma Vol.70, No.4, p. 580–587, 2023
|
| Title: Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment |
| Author: Dongbo Chen, Xiangxun Chen, Lei Xu, Yichun Wang, Liyang Zhu, Mei Kang |
|
Abstract: Although a phase II clinical trial confirmed that camrelizumab combined with apatinib is effective in patients with hepatocellular carcinoma (HCC), we generally lack data on the results of this regimen in real-world clinical practice. In this study, the efficacy and safety of camrelizumab combined with apatinib in the treatment of patients with HCC were re-evaluated. Data from 86 patients with HCC were collected and combinatorically treated with camrelizumab and apatinib at the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China. The objective remission rate and disease control rate were 25.6% and 72.1%, respectively. The median progression-free survival was 5 months (95% CI 3.7–6.3 months), and the median overall survival time was 19.0 months (95% CI 16.9–21.1 months). The 12- and 18-month survival rates were 70.9% and 54.2%, respectively. The most common grade 3-4 adverse events were hypertension (24.4%), thrombocytopenia (16.3%), and hyperbilirubinemia (9.3%). Multivariate regression analysis showed that operation history was an independent risk factor for overall survival.
|
|
| Keywords: hepatocellular carcinoma; safety; efficacy; camrelizumab; apatinib |
|
|
Published online: 03-Oct-2023
|
| Year: 2023, Volume: 70, Issue: 4 |
Page From: 580, Page To: 587 |
doi:10.4149/neo_2023_230413N206
|
|
 download file |
|
|
|
|
